Related content

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

By Delmas P.   Recker R.   Chesnut C.   Skag A.   Stakkestad J.   Emkey R.   Gilbride J.   Schimmer R.   Christiansen C.  

Osteoporosis International, Vol. 15, Iss. 10, 2004-10 ,pp. : 792-798

Springer Publishing Company

Access to resources Recommend Favorite

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

By Harris Steven T.   Blumentals William A.   Miller Paul D.  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 237-245

Informa Healthcare

Access to resources Recommend Favorite

Clinical Effects of a 6-Month Treatment Course of Ibandronate, Vitamin D, and Calcium in Postmenopausal Women from Central America: Results of a Multinational, Prospective Pilot Study

By  

Integrative Medicine International, Vol. 3, Iss. 1-2, 2016-08 ,pp. : 82-88

Karger

Access to resources Recommend Favorite

Clinical Risk Factor Evaluation to Defer Postmenopausal Women From Bone Mineral Density Measurement: An Italian Study

By Gnudi Saverio   Sitta Emanuela  

Journal of Clinical Densitometry, Vol. 8, Iss. 2, 2005-06 ,pp. : 199-205

Humana Press, Inc

Access to resources Recommend Favorite